

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GenFleet Therapeutics (Shanghai) Inc.

勁方醫藥科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2595)

**DATE OF BOARD RESOLUTIONS
AND
DATE OF PUBLICATION OF INTERIM REPORT**

The board of directors (the “**Board**”) of GenFleet Therapeutics (Shanghai) Inc. (the “**Company**”) hereby announces that it will consider and approve the Company’s interim report for the six months ended June 30, 2025, along with its publication and the consideration of the payment of an interim dividend (if any), via written resolutions on Tuesday, September 30, 2025 (Hong Kong Time).

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, September 19, 2025

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors.